NASDAQ:RSLS

ReShape Lifesciences (RSLS) Stock Price, News & Analysis

$0.17
0.00 (-0.24%)
(As of 01:24 PM ET)
Today's Range
$0.17
$0.17
50-Day Range
$0.15
$0.19
52-Week Range
$0.14
$2.80
Volume
169,371 shs
Average Volume
721,700 shs
Market Capitalization
$2.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RSLS stock logo

About ReShape Lifesciences Stock (NASDAQ:RSLS)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

RSLS Stock Price History

RSLS Stock News Headlines

Reshape Lifesciences Inc RSLS
RSLS ReShape Lifesciences Inc.
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Q4 2023 ReShape Lifesciences Inc Earnings Call
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
ReShape Lifesciences Inc (RSLS)
ReShape Lifesciences, Inc.
ReShape Lifesciences Inc.
Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?
See More Headlines
Receive RSLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/13/2020
Today
4/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:RSLS
CUSIP
29365M20
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Net Income
$-11,390,000.00
Net Margins
-131.22%
Pretax Margin
-130.62%

Debt

Sales & Book Value

Annual Sales
$8.68 million
Book Value
$0.51 per share

Miscellaneous

Free Float
13,122,000
Market Cap
$2.23 million
Optionable
Not Optionable
Beta
0.22
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Dan W. GladneyMr. Dan W. Gladney (Age 71)
    Executive Chair
    Comp: $129.5k
  • Mr. Paul F. Hickey (Age 59)
    CEO, President & Director
    Comp: $506.42k
  • Mr. Thomas  StankovichMr. Thomas Stankovich (Age 63)
    Senior VP & CFO
    Comp: $307.12k
  • Dr. Mark B. Knudson Ph.D. (Age 75)
    Co-Founder and Special Advisor to the CEO
    Comp: $33k
  • Dr. Katherine S. Tweden Ph.D. (Age 63)
    Co-Founder
    Comp: $338.41k
  • Mr. Al Diaz
    Vice President of Operations and R&D
  • Dr. Dov Gal D.V.M.
    M.B.A., VP of Regulatory Clinical Quality & Compliance Officer
  • Jody B. Dahlman
    Director of Communications
  • Mr. Naqeeb A. Ansari (Age 63)
    Senior Vice President of Global Commercial Operations
    Comp: $327.46k

RSLS Stock Analysis - Frequently Asked Questions

How have RSLS shares performed in 2024?

ReShape Lifesciences' stock was trading at $0.2497 at the start of the year. Since then, RSLS shares have decreased by 32.2% and is now trading at $0.1694.
View the best growth stocks for 2024 here
.

Are investors shorting ReShape Lifesciences?

ReShape Lifesciences saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 487,800 shares, a drop of 33.1% from the March 31st total of 729,300 shares. Based on an average daily volume of 520,900 shares, the short-interest ratio is currently 0.9 days. Currently, 2.3% of the shares of the company are sold short.
View ReShape Lifesciences' Short Interest
.

When is ReShape Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RSLS earnings forecast
.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) announced its quarterly earnings data on Thursday, August, 13th. The medical device company reported ($8.67) EPS for the quarter, topping analysts' consensus estimates of ($218,400.00) by $218,391.33. The medical device company earned $1.70 million during the quarter. ReShape Lifesciences had a negative net margin of 131.22% and a negative trailing twelve-month return on equity of 187.89%.

When did ReShape Lifesciences' stock split?

ReShape Lifesciences's stock reverse split before market open on Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RSLS) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners